Netazepide

DB12355InvestigationalSmall molecule

Netazepide has been used in trials studying the prevention and treatment of Dyspepsia, Hypergastrinaemia, Barrett's Esophagus, ECL-cell Hyperplasia, and Rebound Hyperacidity, among others.

Mechanism: Pharmacologically active on Gastrin/cholecystokinin type B receptor
Curator reviewed
Formula / weight: C₂₈H₃₀N₆O₃ · 498.587 g/mol (avg)
Code names: YF-476

Resolves to

Compound

UNIIHOU4I0G29CCAS155488-25-8ChEMBLCHEMBL324547PubChem9870520

Structure

InChIKeyYDZYKNJZCVIKPP-VWLOTQADSA-NSMILESCNC1=CC(NC(=O)N[C@@H]2N=C(C3=CC=CC=N3)C3=CC=CC=C3N(CC(=O)C(C)(C)C)C2=O)=CC=C1

Targets

P32239CCKBR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Netazepide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account